切换至比克替拉韦/恩曲他滨/丙酚替诺福韦可维持HIV-1 RNA抑制,包括存在M184V/I耐药突变者
两项切换研究(1878和1844)的事后分析显示,在病毒学抑制的HIV-1成人中,切换至BIC/FTC/TAF后48周病毒学抑制率与继续基线方案相当。在95%(543/570)可评估存档耐药的患者中,40%存在至少一个原发耐药突变,10%检出M184V/I。第48周,整体98%(561/570)、存在耐药者98%(213/217)、M184V/I者96%(52/54)达到HIV-1 RNA<50 copies/mL,且无治疗 emergent 耐药发生。
要点
- 切换至BIC/FTC/TAF在存在存档NRTI耐药(包括M184V/I)的抑制患者中维持高病毒学抑制率。
- 研究未观察到BIC/FTC/TAF治疗期间出现治疗emergent耐药。
- 对既往耐药突变(尤其M184V/I)的抑制患者,BIC/FTC/TAF是有效选择。
核心结论
- 在病毒学抑制的HIV-1感染者中,切换至BIC/FTC/TAF后48周维持高比例病毒学抑制,包括存在存档NRTI耐药(含M184V/I)者,且无治疗emergent耐药发生。
研究设计与样本
- 研究为两项切换研究(1878和1844)的事后分析,评估既往耐药与第48周疗效。
- 耐药评估基于历史基因型和全血基线原病毒DNA基因型,排除对研究药物已有 documented 耐药者。
- 累计获得95%(543/570)切换至BIC/FTC/TAF参与者的历史与原病毒基因型耐药数据。
- 第48周结局基于HIV-1 RNA,缺失值采用末次观察结转法填补。
主要发现
- 40%(217/543)存在至少一个蛋白酶、逆转录酶和/或整合酶原发耐药突变。
- 16%(89/543)检出切换前NRTI耐药,10%(54/543)经原病毒基因型检出M184V或M184I。
- 第48周,整体98%(561/570)、存在耐药者98%(213/217)、M184V/I者96%(52/54)达到HIV-1 RNA<50 copies/mL。
- 无BIC/FTC/TAF治疗参与者出现对研究药物的治疗emergent耐药。
临床怎么用
- 对病毒学抑制但存在存档NRTI耐药(包括M184V/I)的HIV-1感染者,可考虑切换至BIC/FTC/TAF。
- 切换前应评估历史基因型和原病毒DNA耐药,以识别M184V/I等存档耐药。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Studies 1878 and 1844 demonstrated non-inferior efficacy of switching suppressed HIV-1-infected adults to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) versus continuing boosted PI-based triple regimens or dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). Here, detailed analyses of pre-existing resistance in the two BIC/FTC/TAF switch studies and efficacy at week 48 are described. METHODS: Pre-existing resistance was assessed from historical genotypes (documented resistance to study drugs was excluded) and by retrospective baseline proviral archive DNA genotyping from whole blood. Outcomes were based on HIV-1 RNA at week 48 with missing values imputed using the last on-treatment observation carried forward method. RESULTS: Cumulative pre-existing resistance data from historical and proviral genotypes were obtained for 95% (543/570) of participants who switched to BIC/FTC/TAF. Altogether, 40% (217/543) had one or more pre-existing primary resistance substitutions in protease, reverse transcriptase and/or integrase. Pre-switch NRTI resistance was detected in 16% (89/543) of BIC/FTC/TAF-treated participants, with M184V or M184I detected by proviral genotyping in 10% (54/543). At week 48, 98% (561/570) of all BIC/FTC/TAF-treated participants versus 98% (213/217) with pre-existing resistance and 96% (52/54) with archived M184V/I had HIV-1 RNA <50 copies/mL. No BIC/FTC/TAF-treated participants developed treatment-emergent resistance to study drugs. CONCLUSIONS: Pre-existing resistance substitutions, notably M184V/I, were unexpectedly common among suppressed participants who switched to BIC/FTC/TAF. High rates of virological suppression were maintained in the overall study population and in those with pre-existing resistance, including M184V/I, for up to 48 weeks of BIC/FTC/TAF treatment with no resistance development. These results indicate that BIC/FTC/TAF is an effective treatment option for suppressed patients, including those with evidence of archived NRTI resistance.
引用
- Andreatta K, Willkom M, Martin R, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. J Antimicrob Chemother. 2019. PMID: 31430369. doi:10.1093/jac/dkz347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。